Sivik Global Healthcare LLC Grows Position in Humana Inc. (NYSE:HUM)

Sivik Global Healthcare LLC grew its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 15.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,000 shares of the insurance provider's stock after buying an additional 3,000 shares during the period. Humana accounts for about 3.3% of Sivik Global Healthcare LLC's investment portfolio, making the stock its 15th largest position. Sivik Global Healthcare LLC's holdings in Humana were worth $6,086,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of HUM. Dodge & Cox raised its position in shares of Humana by 106.7% during the fourth quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider's stock valued at $2,587,345,000 after buying an additional 5,264,045 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Humana by 15.8% during the fourth quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider's stock valued at $3,254,899,000 after buying an additional 1,751,857 shares during the last quarter. Norges Bank bought a new stake in shares of Humana during the fourth quarter valued at approximately $416,202,000. Pzena Investment Management LLC raised its position in shares of Humana by 44.0% during the fourth quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider's stock valued at $915,736,000 after buying an additional 1,103,132 shares during the last quarter. Finally, Boston Partners raised its position in shares of Humana by 435.8% during the fourth quarter. Boston Partners now owns 1,098,702 shares of the insurance provider's stock valued at $279,236,000 after buying an additional 893,637 shares during the last quarter. Institutional investors own 92.38% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on HUM shares. Cantor Fitzgerald reiterated a "neutral" rating and set a $290.00 price objective on shares of Humana in a research report on Thursday, May 1st. Bank of America reduced their price target on shares of Humana from $320.00 to $260.00 and set a "neutral" rating on the stock in a research report on Tuesday. Truist Financial set a $280.00 price target on shares of Humana and gave the stock a "hold" rating in a research report on Tuesday. Wall Street Zen cut shares of Humana from a "buy" rating to a "hold" rating in a research report on Saturday, June 14th. Finally, Raymond James Financial upgraded shares of Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price target on the stock in a research report on Thursday, May 1st. Seventeen investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $280.76.

Humana Trading Down 1.5%

Shares of HUM traded down $3.74 during trading hours on Friday, reaching $239.66. 2,045,295 shares of the company traded hands, compared to its average volume of 1,812,774. The firm has a market cap of $28.92 billion, a price-to-earnings ratio of 16.95, a PEG ratio of 1.84 and a beta of 0.43. Humana Inc. has a 12-month low of $212.45 and a 12-month high of $406.46. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.71. The stock's fifty day moving average price is $245.76 and its 200 day moving average price is $261.02.

Humana (NYSE:HUM - Get Free Report) last issued its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $10.07 by $1.51. The firm had revenue of $32.11 billion during the quarter, compared to analyst estimates of $32 billion. Humana had a net margin of 1.42% and a return on equity of 14.47%. The business's revenue was up 8.4% on a year-over-year basis. During the same period in the previous year, the firm earned $7.23 earnings per share. Sell-side analysts forecast that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.48%. The ex-dividend date is Friday, June 27th. Humana's dividend payout ratio is currently 25.04%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.